InDex Pharmaceuticals AB

InDex Pharmaceuticals is engaged in the discovery and development of so called DIMS drugs (DIMS: DNA-based Immunomodulatory Sequence) for unmet medical needs in a variety of treatment areas such as inflammation and cancer. The company’s corporate mission is to break new ground in innovative immunotherapy and thus become a preferred research and development partner to large industry players in the biopharmaceutical area.

InDex Pharmaceuticals has a large number of proprietary DIMS compounds in various stages of development. DIMS compounds contain oligonucleotides, which interact with Toll-like Receptors (TLR). These recently discovered TLRs, of which 13 have been described in humans and mice together so far, play a central role in the immune system’s ability to defend its host against threatening pathogens.

Synthetic oligonucleotides are being developed for the treatment of cancer, infectious disease, allergy and asthma as well as vaccine adjuvants. InDex Pharmaceuticals also develops its DIMS compounds to boost the efficacy of anti-inflammatory drug treatments as well as to prevent secondary ischemic damage in tissues such as the heart muscle.